The researchers focused on gefitinib (Iressa), which stops the protein receptor from sending a message to the cancer cells to divide and grow. In their study, reported in the June 24 issue of the New England Journal of Medicine, the drug had a better safety profile and improved survival time with no cancer progression in a significantly higher percentage of patients than did standard chemotherapy.
研究人员重点研究吉非替尼 (易瑞沙），这种成分阻止蛋白质受体向癌细胞发出分裂和成长的信息。他们于6月24日在新英格兰医学杂志上发表研究报告：这种药物在安全性和延长存活时间，阻止癌症进展比标准化疗具有明显较高百分比。
Researchers from the respiratory medicine department at the Tohoku University Hospital in Sendai, Japan chose to investigate gefitinib in part because standard cancer treatments --including surgery, radiation and chemotherapy -- fail to cure most cases of non-small cell lung cancer.
日本仙台东北大学医院呼吸内科的研究人员选择了研究吉非替尼，因为标准的癌症治疗方法包括手术、辐射和化疗治疗非小细胞肺癌在大多数情况下并不成功。
易瑞沙、特罗凯、格列卫，
印度抗癌药邮购中心版权所有
。官方网址：www.india-anticancer.com
|
